These results go on to demonstrate that SRPK1 inhibition switches splicing of PD-1 to generate the antagonistic isoform, which enhances T cell killing of tumour cells, opening up the possibility of small molecule SRPK1 inhibitors as novel pharmacological immunotherapies. The gene discussed is PDCD1; the disease is neoplasm.